Abstract
Idiosyncratic drug toxicity has led to the market withdrawal of many drugs in the past. Since animal experiments are not predictive of such toxicity, the pharmaceutical industry continues to seek new methodologies for the prevention of such effects. Although the mechanism of idiosyncratic drug toxicity remains unclear, immune reactions are likely involved. Although drugs with low molecular weights are typically not themselves immunogenic, these drugs may become haptens after being converted to chemically reactive metabolites and becoming covalently cross-linked to proteins. Therefore, screening tests to detect chemically reactive metabolites, most typically by trapping with glutathione, are carried out at early stages of drug development. More quantitative methods are used in later stages of drug development; radioassays for covalent binding (using 14Cor 3H-labeled compounds) are most frequently employed. A zone classification system created by combining previous assessment criteria for the chemically reactive metabolites in vitro (<50 pmole/mg-protein) and for the dose levels in vivo (<10 mg/day) could be used for risk assessment of drug candidates. A mechanism for idiosyncratic, drug-induced hepatotoxicity is proposed by analogy to virus-induced hepatitis, where cytotoxic T lymphocytes play an important role; we suggest that idiosyncrasy reflects the involvement of polymorphisms in the human leucocyte antigen-encoding loci. In fact, a strong correlation has been found between of idiosyncratic drug toxicity and specific human leucocyte antigen genotypes. Therefore, screening of patients for gene biomarkers is expected to reduce the clinical risk of idiosyncratic drug toxicity, thereby prolonging the life cycle of otherwise useful drugs.
Keywords: Adaptive immune reaction, chemically reactive metabolite, covalent protein binding, cytotoxic T lymphocytes, gene biomarker, go/no-go decision, human leucocyte antigen, idiosyncratic toxicity, innate immune reaction, intrinsic toxicity, judging criteria, risk assessment.
Current Medicinal Chemistry
Title:Idiosyncratic Drug Hepatotoxicity: Strategy for Prevention and Proposed Mechanism
Volume: 22 Issue: 4
Author(s): Toshihiko Ikeda
Affiliation:
Keywords: Adaptive immune reaction, chemically reactive metabolite, covalent protein binding, cytotoxic T lymphocytes, gene biomarker, go/no-go decision, human leucocyte antigen, idiosyncratic toxicity, innate immune reaction, intrinsic toxicity, judging criteria, risk assessment.
Abstract: Idiosyncratic drug toxicity has led to the market withdrawal of many drugs in the past. Since animal experiments are not predictive of such toxicity, the pharmaceutical industry continues to seek new methodologies for the prevention of such effects. Although the mechanism of idiosyncratic drug toxicity remains unclear, immune reactions are likely involved. Although drugs with low molecular weights are typically not themselves immunogenic, these drugs may become haptens after being converted to chemically reactive metabolites and becoming covalently cross-linked to proteins. Therefore, screening tests to detect chemically reactive metabolites, most typically by trapping with glutathione, are carried out at early stages of drug development. More quantitative methods are used in later stages of drug development; radioassays for covalent binding (using 14Cor 3H-labeled compounds) are most frequently employed. A zone classification system created by combining previous assessment criteria for the chemically reactive metabolites in vitro (<50 pmole/mg-protein) and for the dose levels in vivo (<10 mg/day) could be used for risk assessment of drug candidates. A mechanism for idiosyncratic, drug-induced hepatotoxicity is proposed by analogy to virus-induced hepatitis, where cytotoxic T lymphocytes play an important role; we suggest that idiosyncrasy reflects the involvement of polymorphisms in the human leucocyte antigen-encoding loci. In fact, a strong correlation has been found between of idiosyncratic drug toxicity and specific human leucocyte antigen genotypes. Therefore, screening of patients for gene biomarkers is expected to reduce the clinical risk of idiosyncratic drug toxicity, thereby prolonging the life cycle of otherwise useful drugs.
Export Options
About this article
Cite this article as:
Ikeda Toshihiko, Idiosyncratic Drug Hepatotoxicity: Strategy for Prevention and Proposed Mechanism, Current Medicinal Chemistry 2015; 22 (4) . https://dx.doi.org/10.2174/0929867321666140916122628
DOI https://dx.doi.org/10.2174/0929867321666140916122628 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
RAGE: A Single Receptor for Several Ligands and Different Cellular Responses: The Case of Certain S100 Proteins
Current Molecular Medicine Role of Differential Signaling Pathways and Oxidative Stress in Diabetic Cardiomyopathy
Current Cardiology Reviews Neuroprotection by (endo)Cannabinoids in Glaucoma and Retinal Neurodegenerative Diseases
Current Neuropharmacology Biosurfactants as a Novel Additive in Pharmaceutical Formulations: Current Trends and Future Implications
Current Drug Metabolism Pathobiology of Pulmonary Arterial Hypertension
Current Respiratory Medicine Reviews Perioperative Levels of Adiponectin and Oxidative Stress in Patients Undergoing Laparoscopic Abdominal Surgery for Cancer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Xanthine Oxidoreductase in the Pathogenesis of Endothelial Dysfunction: An Update
Current Hypertension Reviews Recent Progress in Structure Activity Relationship and Mechanistic Studies of Taxol Analogues
Mini-Reviews in Medicinal Chemistry The Role of Inflammation and Allergy in Acute Coronary Syndromes
Inflammation & Allergy - Drug Targets (Discontinued) Radiolabeled Organism-Specific Antibodies for Diagnosis and Therapy of Infections
Current Medical Imaging Therapeutic Proteins and Nanotechnology: Immune Response and Stealth Bioengineered Constructs
Current Drug Metabolism Post-Translational Modification of Transcription Factors: Mechanisms and Potential Therapeutic Interventions
Current Molecular Pharmacology Platelet Signaling Induced by Lipoproteins
Cardiovascular & Hematological Agents in Medicinal Chemistry Extraction, Structure and Bioactivities of the Polysaccharides from Fructus corni
Recent Patents on Food, Nutrition & Agriculture Overlapping Molecular Signatures in Parkinson's Patient Leukocytes Before and After Treatment and in Mouse Model Brain Regions
CNS & Neurological Disorders - Drug Targets Antiapoptotic Drugs: A Therapautic Strategy for the Prevention of Neurodegenerative Diseases
Current Pharmaceutical Design Phytochemistry, Antinociceptive and Anti-inflammatory Actvities of Methanolic Leaves Extract of Lannea schimperi (Hoschst. Ex Rich) ENG.
Recent Patents on Biotechnology Synthetic Curcumin Analog UBS109 Inhibits the Growth of Head and Neck Squamous Cell Carcinoma Xenografts
Current Cancer Drug Targets Current status of Immunotherapy in B Cell Malignancies
Current Drug Targets Transforming Growth Factor Beta in Pancreatic Cancer
Current Pharmaceutical Biotechnology